摘要
慢性阻塞性肺病患病率与死亡率高,得到越来越多的药物研发人员的关注。由于传统药物的不良反应与局限性,新型药物的研发至关重要。现阶段研发的热点主要为新型抗胆碱药物、新一代超长效支气管扩张剂、新型磷酸二酯酶-4抑制剂、内皮素抑制剂、蛋白酶抑制剂等,其代表性药物分别为格隆溴铵、茚达特罗、罗氟司特、bimosiamose、米地司坦等。对慢性阻塞性肺病的新型药物的研发进展与前景进行综述。
Given the high morbidity and mortality of chronic obstructive pulmonary disease （COPD）, more drug developers get attention to it. Due to the adverse reaction and limitation of traditional medicines, the study and development of the new drug are very important. At present, hot spots in the research of main stage are new anticholinergic drugs, new generation of ultra-long-acting bronchodilators, new phosphodiesterase-4 （PDE-4） inhibitors, endothelin inhibitors, and protease inhibitors etc. The representative drugs are glycopyrrolate bromide, indacaterol, roflumilast, bimosiamose, midesteine, respectively. In this paper, the development and prospect of the new drug on COPD have been reviewed.
出处
《现代药物与临床》
CAS
2011年第5期333-338,共6页
Drugs & Clinic
关键词
慢性阻塞性肺病
抗胆碱药
支气管扩张剂
磷酸二酯酶-4抑制剂
内皮素抑制剂
蛋白酶抑制剂
chronic obstructive pulmonary disease （COPD）
anticholinergic drug
bronchodilator
phosphodiesterase-4 （PDE-4）inhibitors
endothelin inhibitor
protease inhibitor
